Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today unveiled new real-world EMEA physician preference data for the SOFIA Flow 88 Aspiration Catheter at the 2025 European Society of Minimally Invasive Neurological Therapy (ESMINT) 17th Annual Congress. The data—presented publicly for the first time —demonstrates strong performance compared to other aspiration catheters1 in key performance metrics such as trackability, navigation and overall physician-rated experience.
Collected from 70 procedures across 16 EMEA Hospitals and 31 physicians, the preference test revealed:
- 83% of physicians reported that SOFIA Flow 88 catheter reliably reached the target location—even in anatomically challenging cases, with 76% of procedures in ICA-T or beyond
- 100% of physicians rated SOFIA Flow 88 catheter “Same” or “Better” than SOFIA Plus 6F for ease of trackability to target vessel location
- 92% of physicians rated the SOFIA Flow 88 catheter as “Same”, “Better” or “Much Better” than alternative aspiration catheters overall
“The SOFIA Flow 88 Neurovascular Aspiration Catheter represents a meaningful advancement in mechanical thrombectomy therapy across EMEA,” said Carsten Schroeder, President and CEO of Terumo Neuro. “Its super bore design maximizes aspiration and minimizes flow disruption while delivering exceptional support. It enables physicians to navigate even the most tortuous anatomies in an atraumatic fashion. We’re proud that physician preference data so clearly underlines SOFIA Flow 88 catheter’s strong performance. It reinforces the SOFIA catheter family’s reputation as ‘best in class’ for trackability, navigation and overall performance.”
The SOFIA Flow 88 Neurovascular Aspiration Catheter was commercially launched in the EMEA on June 2, 2025, as the latest addition to Terumo Neuro’s global stroke portfolio. Engineered for reliable trackability, proximal stability, and vessel-friendly flexibility, the SOFIA Flow 88 catheter is designed to optimize physician control and integration into a variety of aspiration and combination strategies.
The physician preference data unveiled at ESMINT builds on results from the U.S.-based SOFAST data and the European SESAME Study, which demonstrated the safety and efficacy of the SOFIA™ catheter as a frontline approach in mechanical thrombectomy.
The SOFIA Flow 88 catheter is compatible with the SOFIA™ Plus 6F Aspiration Catheter and is part of Terumo Neuro’s fully integrated stroke solution, including:
- ERIC™ Retrieval Device – For thrombus control and procedural versatility
- BOBBY™ Balloon Guide Catheter – Offering reliable2 flow arrest with next-gen balloon technology
- WEDGE™ and HEADWAY™ Microcatheters – Designed for navigation support and access efficiency
- TRAXCESS™ Guidewires – Soft-tip wires built for challenging anatomies
